surmount-1 tirzepatide Nutritional status with in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials surmount-1 tirzepatide trial obesity without

PubMed Kaux J-F, et al

Should not be consumed on an empty stomach

The rHrGSTm1 showed a certain degree of antioxidant activity and a certain scavenging ability to DPPH

doi: 10.1136/bmj.c869 Summary Keywords obesity, GLP-1, GLP-1 receptor analog, exenatide, pediatrics, glycemic control, GLP-1 receptor agonist, treatment Citation Stenlid R, Cerenius SY, Wen Q, Aydin BK, Manell H, Chowdhury A, Kristinsson H, Ciba I, Gjessing ES, Mrwald K, Gomahr J, Heu V, Weghuber D, Forslund A and Bergsten P (2023) Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control

A.KitabatakeY.MingG

Tirzepatide (Mounjaro/Zepbound) : fino al 26% (SURMOUNT-1 e SURMOUNT-5)